SeaLA
Commercial- Indications
- Stroke prevention, Left atrial appendage closure
Company intelligence / Profile preview
Dinova EP Technology has developed and commercialized innovative interventional medical devices targeting atrial fibrillation and stroke prevention. Its flagship products include the CardioPulse™, a pulse field ablation system that completed Asia’s first pulsed field ablation procedures for both paroxysmal and persistent AF by mid–2021, and the SeaLA™, a left atrial appendage closure device. The company focuses on advancing electrophysiology solutions with demonstrated early clinical adoption in Asia.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dinova EP Technology.